Company intelligence / Profile preview

BODi

Chuncheon, Gangwon-do, South Koreabeachbodyondemand.com ↗

Ownership: Private
Employees: ~56
Development stage: Commercial

Overview

Boditech Med is a global provider of in vitro diagnostic (IVD) solutions, emphasizing point-of-care immunodiagnostics and molecular diagnostics. The company’s diagnostic kits are WHO listed for neglected tropical diseases, including dengue, and have regulatory approval in various regions. As of 2025, they report expansion into biochemistry, hematology, and veterinary diagnostics, with products in global markets and a strong emphasis on quality and compliance with regulatory standards[3].

Therapeutic areas: Infectious DiseasesEndocrinologyCardiovascular
Modalities: Diagnostic kitMedical deviceIn vitro diagnostic
Industry: Molecular Diagnostics

Partnerships

SphingoTec (joint development of AFIAS penKid® kidney function assay)[5]

Beyond the preview

Go deeper on BODi.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on BODi.

Explore the full profile